Biotech News Butler
Aldeyra reproxalap hits third FDA CRL
3 articles curated from biotech news
Aldeyra dry eye drug gets third rejection from FDA, triggering stock slide
Endpoints News
Mar 17, 2026
Aldeyra collects third CRL for reproxalap in dry eye disease
BioWorld (Clarivate)
Mar 17, 2026
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting
BioSpace
Mar 17, 2026
Share:
Post
Share
Want daily biotech news like this?
Sign up free